Our findings demonstrate that SFV vectors, particularly those engineered to deliver TNFα or IFNγ, can reprogramme macrophages towards an anti-tumour phenotype, with substantial implications for cancer immunotherapy. The gene discussed is IFNG; the disease is neoplasm.